Human Epidermal Growth Factor Receptor
The epidermal growth factor family of receptor tyrosine kinases (ErbBs) plays essential roles in regulating cell proliferation, survival, differentiation and migration. The ErbB receptors carry out both redundant and restricted functions in mammalian development and in the maintenance of
tissues in the adult mammal. Loss of regulation of the ErbB receptors underlies many human diseases, most notably cancer. Our understanding of the function and complex regulation of these receptors has fueled the development of targeted therapeutic agents for human malignancies in the last 15 years. Here we review the biology of ErbB receptors, including their structure, signaling, regulation, and roles in development and disease, then briefly touch on their increasing roles as targets for
cancer therapy. Growth factors are essential for the development, growth and
homeostasis of multicellular organisms. Acting through cell surface receptors, growth factors are required for cell-cell communications underlying embryonic tissue induction, fate determination, cell survival, apoptosis, tissue specialization and cell migration. Growth factor receptors transduce extracellular signals through the activation of intracellular messengers or directly through receptor translocation to the nucleus. Of the receptor tyrosine kinases (RTKs), the epidermal growth factor (EGF) family of RTKs, also called ErbB or HER receptors, is one of the most extensively studied for its role in development, physiology, and human cancer
High Impact List of Articles
-
Strategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancer
Rowan T Chlebowski
Review: Clinical Trail Outcomes: Clinical Investigation
-
Strategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancer
Rowan T Chlebowski
Review: Clinical Trail Outcomes: Clinical Investigation
-
Estimating site costs prior to conducting clinical trials
Dorothee Arenz, Barbara Hero, Barbara F Eichhorst, Martin Langer, Lars Pester, Julia von Tresckow, Jrg J Vehreschild, Maria JGT Vehreschild, Oliver A Cornely
Special Report: Clinical Investigation
-
Estimating site costs prior to conducting clinical trials
Dorothee Arenz, Barbara Hero, Barbara F Eichhorst, Martin Langer, Lars Pester, Julia von Tresckow, Jrg J Vehreschild, Maria JGT Vehreschild, Oliver A Cornely
Special Report: Clinical Investigation
-
Challenges and opportunities in the design and implementation of breast cancer clinical trials in the developing countries
Sudeep Gupta, Shona Nag, Shaheenah Dawood
Clinical Trail Perspective: Clinical Investigation
-
Challenges and opportunities in the design and implementation of breast cancer clinical trials in the developing countries
Sudeep Gupta, Shona Nag, Shaheenah Dawood
Clinical Trail Perspective: Clinical Investigation
-
New considerations in the design of clinical trials for traumatic brain injury
Bob Roozenbeek, Hester F Lingsma Andrew I R Maas
Clinical Trail Methodology: Clinical Investigation
-
New considerations in the design of clinical trials for traumatic brain injury
Bob Roozenbeek, Hester F Lingsma Andrew I R Maas
Clinical Trail Methodology: Clinical Investigation
-
Inhibitors of JAK for the treatment of rheumatoid arthritis: rationale and clinical data
Charles J Malemud
Therapeutic Perspective: Clinical Investigation
-
Inhibitors of JAK for the treatment of rheumatoid arthritis: rationale and clinical data
Charles J Malemud
Therapeutic Perspective: Clinical Investigation
Relevant Topics in Clinical